Unjha Formulations

Unjha Formulations Forward P/E

The Forward P/E Ratio of Unjha Formulations (531762.BO) as of Oct 27, 2026 is 14.65. In the previous year, Forward P/E Ratio was 25.33 — a change of -42.17% (lower).

Forward P/E

14.65

YoY

-42.17%

Last updated:

Forward P/E Ratio of Unjha Formulations is 2026 14.65 . Forward P/E Ratio of Unjha Formulations was 2025 25.33 . It decreases by -42.17% lower compared to the previous year.

The Unjha Formulations Forward P/E history

  • 3 Years

  • 10 Years

  • 25 Years

  • Max

Forward P/E
Date
Forward P/E
Jan 1, 2019
34.38 INR
Jan 1, 2020
33.48 INR
Jan 1, 2021
99.70 INR
Jan 1, 2022
40.88 INR
Jan 1, 2023
36.54 INR
Jan 1, 2024
37.15 INR
Jan 1, 2025
25.33 INR
Jan 1, 2026
14.65 INR
The Unjha Formulations Forward P/E history
YEARForward P/EYoY
14.65-42.17%
25.33-31.80%
37.15+1.66%
36.54-10.62%
40.88-58.99%
99.70+197.82%
33.48-2.62%
34.38-12.55%
39.31+12.55%
34.93-12.94%
40.12-32.47%
59.41-28.45%
83.03—

Access this data via the Eulerpool API

100,000 free requests/mo · no credit card

Get Free API Key

Unjha Formulations Stock analysis

What does Unjha Formulations do? Unjha Formulations Ltd. generates revenue through the manufacturing and export of Ayurvedic products, primarily targeting international markets. The company's key products include Fibron SF Powder, Albendazole Bolus, and Fibermate, which are isabgol-based formulations. Anchor Sat-Isabgol, available in 50g, 100g, 200g, and 400g sizes, is a flagship product, while Fibron and Fibron SF (Sugar Free) come in 100g and 300g packages. The firm focuses on export markets for its veterinary medicinal formulations not for human use, alongside its Ayurvedic powder and tablet lines. The company's revenue streams are derived from the sale of Fibron SF Powder, Albendazole Bolus, and Fibermate to international buyers seeking Ayurvedic and veterinary products. Anchor Sat-Isabgol is sold in multiple sizes, catering to consumer demand for isabgol-based health supplements. Unjha Formulations Ltd. also produces Small Volume Ayurvedic Isabgol powder, which is exported globally. The primary customers are international importers and distributors specializing in Ayurvedic and veterinary medicinal products. Export markets drive the company's business model, with Fibron SF Powder and Fibron being key revenue contributors. The firm's veterinary medicinal formulation not for human use, including Albendazole Bolus, targets agricultural and livestock sectors. Anchor Sat-Isabgol's availability in various sizes ensures broad market reach, while the company's focus on isabgol-based formulations aligns with global demand for natural health products. Unjha Formulations is one of the most popular companies on Eulerpool.

Frequently Asked Questions about Unjha Formulations stock

Forward P/E Ratio of Unjha Formulations is 14.65 in 2026.

Forward P/E Ratio of Unjha Formulations changed from 25.33 to 14.65, representing a -42.17% change. The value is lower than the previous year.

On Eulerpool you can find the complete historical development of Forward P/E Ratio Unjha Formulations since 2006 – with annual values, charts, and detailed analysis.

The Forward P/E uses estimated future earnings to value a stock. A lower forward P/E relative to the trailing P/E suggests analysts expect earnings growth.

To evaluate Forward P/E Ratio's, it is essential to compare it with peers in the same industry and sector. On Eulerpool, you can find direct industry comparisons for Forward P/E Ratio.

A 'good' varies by industry and company stage. On Eulerpool, you can compare Forward P/E Ratio's Unjha Formulations with sector peers and the industry average to assess whether it is attractive.

Access this data via the Eulerpool API

100,000 free requests/mo · no credit card

Get Free API Key

Valuation — Unjha Formulations

P/EP/SEV/EBITP/BP/CFP/FCFPEGEV/RevenueEV/EBITDAEV/FCFEarnings YieldFCF YieldMarket capitalizationEnterprise ValueForward P/EP/TBVShareholder YieldBuyback YieldDiv.-Adj. PEGEV/OCF

All Key Metrics — Unjha Formulations